Journal: PLOS One
Article Title: Targeted knockdown of DNA methyltransferase 3a (DNMT3a) unlocks dedifferentiation and neurogenic potential in mouse retinal Müller glia
doi: 10.1371/journal.pone.0337891
Figure Lengend Snippet: (A–C) Time-course analysis of mRNA expression levels of progenitor markers Ascl1, Nestin and Lin28 , normalized to Gapdh , measured by qRT-PCR. NMDA and DNMT3a KD alone transiently upregulated these markers, with a more pronounced and sustained effect observed in the DNMT3a KD NMDA group. Data represent mean ± SEM of three independent experiments; *p < 0.05 vs. CTRL at the corresponding point (two-way ANOVA with Tukey’s post hoc test). (D) Quantification of Lin28 fluorescence intensity in arbitrary units (A.U.) from immunocytochemistry images shown in (E). Significant increases in Lin28 expression were observed in NMDA, DNMT3a KD and DNMT3a KD NMDA groups compared to CTRL (*p < 0.05 vs. CTRL; #p < 0.05 vs. NMDA; one-way ANOVA with Tukey’s post hoc test). (E) Representative phase contrast and immunofluorescence images showing DAPI (nuclei, blue) and Lin28 (green) staining at 48 h post-treatment. CTRL: control, NMDA: exposure to NMDA 100 µM, MOCK: electroporation without plasmid, dCas9: transfection of empty plasmid, CRISPRi: CRISPR interference-mediated Dnmt3a knockdown, CRISPRi NMDA: Dnmt3a knockdown with simultaneous exposure to NMDA 100 µM. Phase contrast images scale bar = 100 μm, 10X; Immunofluorescence images scale bar = 20 µm, 40X.
Article Snippet: After that the samples were incubated with following primary antibodies: mouse monoclonal anti-βlll tubulin antibody (Santa Cruz sc-80005) (1:300); rabbit polyclonal anti-GS antibody (Abcam ab73593) (1:300); mouse monoclonal anti-nestin antibody (Santa Cruz sc-23927) (1:200); rabbit polyclonal anti-Lin28 (Abcam ab46020) (1:200) diluted in 1:3 blocking solution at 4°C overnight.
Techniques: Expressing, Quantitative RT-PCR, Fluorescence, Immunocytochemistry, Immunofluorescence, Staining, Control, Electroporation, Plasmid Preparation, Transfection, CRISPR, Knockdown